Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697311 | 0.89 | MAPT (0.75) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697310 | 0.88 | MAPT (0.80) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697159 | 0.88 | MAPT (0.72) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697174 | 0.86 | MAPT (0.77) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697166 | 0.86 | MAPT (0.69) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697274 | 0.86 | MAPT (0.69) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697281 | 0.85 | KMT2A (1.00) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL14697267 | 0.85 | MAPT (0.81) | MAPTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL14697131 | 0.85 | MAPT (0.74) | MAPTKMT2ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL14697132 | 0.84 | MAPT (0.81) | MAPTKMT2ASMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | claimed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | claimed |
| EP-2744787-B1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RES INST (US) | 2016-11-02 | — | — | EP | claimed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | claimed |
| EP-2744787-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | Southern Research Institute (US) | 2014-06-25 | — | — | EP | claimed |
| WO-2013025508-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | WO | claimed |
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE | 2017-05-25 | — | — | US | disclosed |
| US-9598402-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | SOUTHERN RESEARCH INSTITUTE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2744787-B1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RES INST (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2744787-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | Southern Research Institute (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013025508-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256753-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | HAVCR2, EIF2AK2, GLS2 | MAPT 1316/4885KMT2A 3419/4885SMN1; SMN2 888/4885 |
| US-20170144978-A1 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS | ZC3HAV1, EIF2AK2, GTF3C3 | MAPT 1974/4885KMT2A 3065/4885SMN1; SMN2 1909/4885 |
| US-10611733-B2 | Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections | ZC3HAV1, EIF2AK2, GTF3C3 | MAPT 1974/4885KMT2A 3065/4885SMN1; SMN2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.